Case Series

Comparative analysis of clinicopathologic features between adenoma and hyperplasia in surgically treated patients for hyperparathyroidism: A retrospective study

Boubacar Efared, Rabiou Sani, Layla Tahiri, Mohamed Smahi, Khalid Mazaz, Abdelmalek Ousadden, Laila Chbani

* Corresponding author. Faculty of Health Sciences, Abdou Moumouni University, Niamey, BP 10896, Niger.
E-mail address: befared2013@gmail.com (B. Efared).

https://doi.org/10.1016/j.amsu.2021.102929
Received 11 September 2021; Received in revised form 5 October 2021; Accepted 7 October 2021
Available online 9 October 2021

ARTICLE INFO

Keywords:
Hyperparathyroidism
Parathyroid adenoma
Parathyroid hyperplasia
PTH
Calcium

ABSTRACT

Background: Hyperparathyroidism (HPT) is a common endocrine disorder resulting from overproduction of parathyroid hormone (PTH). Usually HPT is caused by parathyroid adenoma (PA) or parathyroid hyperplasia (PH). Our aim is to assess clinicopathologic features associated with PA and PH in patients with HPT.

Methods: We retrospectively collected 29 cases of HPT recorded at the Department of Pathology of Hassan II University Hospital of Fes, Morocco, from 2013 to 2016.

Results: The mean age was 52.14 ± 15.7 years (range of 22–76 years), 13 patients (44.8%) had primary HPT, 16 (55.2%) had secondary HPT. The largest size of the resected parathyroid specimens ranged from 1 to 3.6 cm (mean of 2.26 ± 0.66 cm). Seventeen patients (58.6%) had PA, the remaining cases were diagnosed as PH. There were no significant statistical differences between PA and PH in age, sex, clinical presentation, preoperative serum PTH, or in parathyroid gland size (P > 0.05). However compared to PH, PA is more often a single-gland disease, found in primary HPT with higher preoperative calcium level (P < 0.05).

Conclusions: In patients surgically treated for HPT, PA is associated with some distinctive clinicopathologic features. These findings could be helpful to pathologists and clinicians for appropriate clinicopathologic management.

1. Introduction

Hyperparathyroidism (HPT) is a common endocrine disorder resulting from overproduction of parathyroid hormone (PTH) by parathyroid glands [1,2]. Overproduction of PTH may be a consequence of hypocalcemia, hyperphosphatemia (secondary HPT) or may be a result of autonomous parathyroid glands hyperfunction in the absence of a known stimulus (primary HPT) [3]. Primary HPT (pHPT) is associated with hypercalcemia, it is often a sporadic disease with about 5% cases resulting from hereditary syndromes (multiple endocrine neoplasia syndromes (MEN), hyperparathyroidism-jaw tumor, familial hypercalciuric hypercalcaemia, familial hypercalciuric hypercalcaemia or isolated familial HPT) [1]. On the other hand, secondary HPT (sHPT) is a consequence of PTH hypersecretion in response to metabolic disorders (hypocalcemia, hyperphosphatemia, low serum vitamin D) often found in chronic renal failure [3–5]. Tertiary HPT is defined as autonomous parathyroid hyperfunction in a background of sHPT [3]. The clinical symptoms of HPT vary widely from asymptomatic to urinary tract stones, bone demineralisation, bone fracture, fatigue or headache [1–3]. Histologically, patients with HPT present with parathyroid adenoma (PA), parathyroid hyperplasia (PH) or very rarely with parathyroid carcinoma [1,6]. Parathyroid adenoma is a clonal disease and affects usually one gland whereas PH is often a polyclonal disease and affects all parathyroid glands [6–8]. As a consequence, the surgical treatment of PA consists of a minimally invasive approach whereas PH requires more invasive surgical approach [6–10]. Adenoma is more frequent in
patients with pHPT while PH is often found in patients with sHPT, however PA or PH could be encountered in both pHPT and sHPT [1–3, 6].

The objective of our current study is to assess clinical, biochemical and histologic features associated with PA and PH in patients with hyperparathyroidism. The knowledge of these features would lead clinicians to better select patients for appropriate surgical management. This work has been reported in line with the PROCESS 2020 criteria [11].

2. Methods

2.1. Patients selection

This was a retrospective study including 29 consecutive patients with HPT (primary or secondary HPT) recorded at the Department of Pathology of Hassan II University Hospital of Fes, Morocco, from 2013 to 2016. Available clinical, biochemical and pathologic data were collected from patients’ request forms, pathology records and the patients’ medical online records. Preoperative neck ultrasound and technetium-99m-sestamibi scan (Fig. 1) were performed in all cases. All patients underwent surgical resection and were successfully treated with minimum follow-up of 3 months post-operatively. Patients with incomplete data were excluded from the study (3 patients excluded for incomplete data).

2.2. Histopathologic analysis

The histologic analysis was performed on formalin fixed and paraffin-embedded tissue sections with hematoxylin-eosin staining (H&E). The diagnosis of PA and PH were made in accordance with previously described histologic criteria: presence or absence of capsule, presence or absence of fat cells, coexistence with normal parathyroid tissue, cell types in the lesion [12,13].

2.3. Statistics

Patients were divided into 2 groups: PA group and PH group. Differences in the distribution of variables between the 2 groups were assessed using the Fisher exact test or chi-square test (for categorical variables) and Student’s t-test (for non-categorical variables). Results were considered statistically significant when \( P < 0.05 \). Data are presented as mean \( \pm \) SD (standard deviation) or as number (percentage).

This study was registered in the research registry with UIN researchregistry7124 (link: https://www.researchregistry.com/browse-the-registry#home/)

3. Results

We have recorded 29 patients surgically treated for HPT, the mean age was 52.14 \( \pm \) 15.7 years (range of 22–76 years), 18 patients (62.1%) had \( \geq \) 50 years (Table 1). Females were predominantly affected (22 cases, 75.9%). Osteoarticular symptoms (bone pain, osteoporosis, or bone fracture) were present in 23 cases (79.3%), 4 patients (13.8%) had recurrent kidney stones. Concomitant thyroid gland hyperplasia was

| Clinicopathologic features of patients with hyperparathyroidism. |
|---------------------------------------------------------------|
| **Sex**    | Number | Percentage (%) |
| --- | --- | --- |
| Males | 7 | 24.1 |
| Females | 22 | 75.9 |
| **Age**    | | |
| Mean \( \pm \) SD | 52.14 \( \pm \) 15.7 | – |
| \( \leq \) 50 years | 11 | 37.9 |
| \( \geq \) 50 years | 18 | 62.1 |
| **Clinical symptoms** | | |
| Urinary tract | 4 | 13.8 |
| Osteoarticular | 23 | 79.3 |
| Both | 2 | 6.9 |
| **HPT cause** | | |
| Primary | 13 | 44.8 |
| Secondary | 16 | 55.2 |
| **Thyroid gland hyperplasia** | | |
| Absent | 18 | 62.1 |
| Present | 11 | 37.9 |
| **Nb of glands** | | |
| 1 gland | 13 | 44.8 |
| \( > \) 1 gland | 16 | 55.2 |
| **Localisation** | | |
| Eutopic gland | 26 | 89.7 |
| Ectopic gland | 3 | 10.3 |
| **Gland size (largest)** | | |
| Mean \( \pm \) SD | 2.26 \( \pm \) 0.66 | – |
| \( \leq \) 3 cm | 22 | 75.9 |
| \( \geq \) 3 cm | 7 | 24.1 |
| **Histologic lesion** | | |
| Adenoma | 17 | 58.6 |
| Hyperplasia | 12 | 41.4 |
| **Cellular type (predominant)** | | |
| Chief cells | 23 | 79.3 |
| Clear cells | 6 | 20.7 |
| **Biochemistry** | | |
| PTH (Mean \( \pm \) SD) (pg/mL) | 1276.59 \( \pm \) 761.757 | – |
| Calcium (Mean \( \pm \) SD) (mg/L) | 114.35 \( \pm \) 18.22 | – |

Fig. 1. Sestamibi scan in a patient with primary hyperparathyroidism showing anterior mediastinal hyperfixation due to ectopic parathyroid adenoma.
distinctive clinical, biochemical and histopathologic characteristics be

Most patients had eutopic parathyroid glands (26 cases, 89.7%), 3 patients (10.3%) had ectopic parathyroid glands (2 cases with intrathyroid location and 1 case with intrathyroid location). Sixteen patients (55.2%) had multiglandular disease (double PA or PH). The largest size of the resected parathyroid specimens ranged from 1 to 3.6 cm (mean of 2.26 ± 0.66 cm) (Fig. 2A, B, 2C). At histologic analysis, 17 patients (58.6%) had PA (Fig. 3A), the remaining cases were diagnosed as PH (Fig. 3B). Chief cell-type lesions were the predominant histologic variant in both PA and PH, with rare clear cell-type lesions. All 3 ectopic lesions were PA embedded in the thyroid gland or in the thymus.

There were no significant statistical differences between PA and PH in age, sex, clinical presentation, in thyroid gland status or in lesion cellular type (P > 0.05) (Table 2). Also, gland size is not significantly different between these 2 histologic entities (mean of 2.27 ± 0.66 cm for PA and 2.24 ± 0.68 cm for PH; P = 0.910). Parathyroid adenoma (PA) is usually a monoglandular disease (13 cases, 76.5%) and PH is always a multiglandular disorder (P < 0.001). In fact all cases of PH are multiglandular, while 4 patients (23.5%) had double PA. Parathyroid adenoma (PA) is more frequent in patients with pHPT (11 cases, 64.7%) whereas PH is more found in patients with sHPT (10 cases, 83.3%) (P = 0.022). Only 2 patients (16.7%) with sHPT had PA. Also, there was a significant statistical difference between patients with PA and PH in serum calcium (mean of 121.16 ± 19.642 mg/L for PA, 104.69 ± 10.535 mg/L for PH; P = 0.014). Patients with PA had lower level of serum PTH than those with PH, however the difference was not significant (P = 0.127).

4. Discussion

Through our current retrospective study, we have tried to find distinctive clinical, biochemical and histopathologic characteristics between PA and PH in patients with HPT whether primary or not. Parathyroid adenoma or hyperplasia could be found in primary HPT (pHPT) or in secondary HPT (sHPT) with variable incidences [1–3]. As these 2 histologic entities (PA and PH) could be found in pHPT or sHPT, we find logic to include patients with both type of HPT although many authors used to report separately patients with pHPT or sHPT [5,7,12,14–18].

Patients with secondary hyperparathyroidism by definition have diffuse hyperplasia as it is a secondary process stimulating all of the glands. If patients with secondary hyperparathyroidism develops an adenoma, then they have primary and secondary hyperparathyroidism. Occasionally patients with long standing secondary hyperparathyroidism can develop autonomous nodules within their background of hyperplasia and convert to tertiary hyperparathyroidism. The clinical features of our patients are quite similar to those in previous reports, with a mean age around 50 years and a marked female predominance [16,17,19]. All patients of our cohort were symptomatic with osteoarticular symptoms (79.3%, n = 23, with 4 cases of bone fracture), urinary lithiases (13.8%, n = 4) or with both osteoarticular and urinary tract symptoms (6.9%, n = 2). In our study, there were no significant differences in age, sex and clinical presentation between patients with PA and PH (P > 0.05). Previously, some authors have reported asymptomatic patients with HPT, and symptoms had been linked to the duration of the disease [14, 17].

In our study, 16 patients (55.2%) had sHPT due to chronic renal failure, and the remaining cases (n = 13, 44.8%) had pHPT with 1 case of MEN type 2A. Parathyroid adenoma was mostly diagnosed in patients with pHPT (64.7%, n = 11), whereas PH was more frequent in patients with sHPT (83.3%, n = 10), (P = 0.022). As a consequence, serum calcium level was higher in patients with PA than those with PH (respective means of 121.16 ± 19.642 mg/L and 104.69 ± 10.535 mg/L; P = 0.014). Patients with PH had higher serum PTH level than patients with PA, however the difference was not statistically significant (P = 0.127). As most cases of PH were encountered in sHPT (hypocalcemic disorder), it seems normal to find lower serum calcium level in these patients when compared to PA that was more often diagnosed in patients with pHPT. In the literature, data including patients with pHPT and sHPT are very scarce [19,20]. As in our study, it is well established that PA is more frequently associated with pHPT while PH is more frequent in sHPT [1–3]. In patients with pHPT, there were conflicting data between PA (often a single-gland disease) and PH (multigland-disease) in regard to preoperative serum calcium and PTH [7,8,15]. We have found that in patients with HPT, PA is usually a single-gland disease (76.5%, n = 13; P < 0.001), and there was no significant difference between PA and PH in size (respective mean size of 2.27 ± 0.666 cm and 2.24 ± 0.682 cm; P = 0.910), unfortunately we have no data about specimens’ weight. In their study on 260 cases of pHPT Sun. et al. found no statistical difference in parathyroid gland size between patients with PA and PH, however they found that parathyroid carcinoma had higher size than PA and PH [17].

Fig. 2. Macroscopic view of a case of parathyroid adenoma showing a well-encapsulated nodule (A). The cut surface shows grayish lesion with microcystic and hemorrhagic changes (B). Macroscopic view of a case of parathyroid hyperplasia. The cut surface shows enlarged gland with yellowish and homogenous aspect (C).
In patients surgically treated for hyperparathyroidism (HPT), unlike parathyroid hyperplasia (PH) parathyroid adenoma (PA) is a single-gland disease frequently associated with primary hyperparathyroidism (pHPT). These findings could be helpful to pathologists and clinicians for appropriate histopathologic diagnosis and clinical management.
Ethical approval

As a retrospective study and as data had been de-identified ethical approval is not required in our institution (not applicable).

Sources of funding

This study has not received any funding.

Author contribution

BE, wrote the article and made substantial contributions to conception and design of the article; RS, LT, MS, KM, and AO have been involved in drafting the manuscript and revising it critically for important intellectual content. LC has been involved in drafting the manuscript and revising it critically for important intellectual content. All authors read and approved the final version of the manuscript.

Consent

Not applicable.

Registration of research studies

1. Name of the registry: This study was registered in the research registry with UIN researchregistry7124.
2. Unique Identifying number or registration ID: researchregistry7124.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): https://www.researchregistry.com/browse-the-registry#home/

Guarantor

Boubacar Efared.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Declaration of competing interest

All authors declare that they have no competing interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2021.102929.

References

[1] K. Duan, K. Gomez Hernandez, O. Mete, Clinicopathological correlates of hyperparathyroidism, J. Clin. Pathol. 68 (2015) 771–787.
[2] R.A. DeLellis, Parathyroid tumors and related disorders, Mod Pathol Off J U S Can Acad Pathol Inc 24 (Suppl 2) (2011) S78–S93.
[3] Z.W. Baloch, V.A. LiVolsi, Pathology of the parathyroid glands in hyperparathyroidism, Semin. Diagn. Pathol. 30 (2013) 165–177.
[4] J.C. Bucero, J.C. Arevalo, J. Anton, G. Atrado, J.I. Jimenez Morales, N.R. Robles, et al., Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine, Endocrinol Nutr Organo Soc Espanola Endocrinol Nutr 62 (2015) 300–305.
[5] L. Fang, B. Tang, D. Hou, M. Meng, M. Xiong, J. Yang, Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism, BMC Nephrol. 16 (2015) 82.
[6] J.A. Wiesene, A. Smith, Parathyroid adenoma, Head Neck Pathol 2 (2008) 305–308.
[7] E. Kebebew, J. Hwang, E. Reiff, Q.-Y. Duh, O.H. Clark, Predictors of single-gland vs multigland parathyroid disease in primary hyperparathyroidism: a simple and accurate scoring model, 1960, Arch Surg Chic Ill 131 (2006) 777–782. discussion 782.
[8] C.R. McHenry, H.H. Shi, Can parathyroid hyperplasia be predicted preoperatively? Am. J. Surg. 215 (2018) 389–392.
[9] S.L. Stratmann, J.A. Kahn, M.S. Bell, J.T. Prenkitt, J.C. O’Brien, D.R. Gable, et al., Comparison of quick parathyroid assay for uniglandular and multiglandular parathyroid disease, Am. J. Surg. 184 (2002) 578–581, discussion 581.
[10] G. Mozes, K.J. Carlee, C.M. Rowland, J.A. van Heerden, G.B. Thompson, C. S. Grant, et al., The predictive value of laboratory findings in patients with primary hyperparathyroidism, J. Am. Coll. Surg. 194 (2002) 126–130.
[11] R.A. Agha, C. Sobradi, G. Mathew, T. Franchi, A. Kerwan, N. O’Neill, et al., The PROCESS 2020 guideline: updating consensus preferred reporting of CasSeries in surgery (PROCESS) guidelines, Int J Surg Lond Engl 84 (2020) 231–235.
[12] O. Ljungberg, S. Tlibbin, Peroperative fat staining of frozen sections in primary hyperparathyroidism, Am. J. Pathol. 95 (1979) 633–641.
[13] L. Bornstein-Quevedo, A. Gambou-Dominguez, A. Angeles-Angeles, E. Reyes-Gutierrez, F. Vargas-Vasalavkova, R. Gamiño, et al., Histologic diagnosis of primary hyperparathyroidism: a concordance analysis between three pathologists, Endocr. Pan 12 (2001) 49–54.
[14] B. Gao, Y. Jiang, S. Zhang, L. Guo, W. Tian, Y. Wen, et al., Surgical diagnosis and treatment of primary hyperparathyroidism: analysis of 19 cases, Int. J. Clin. Exp. Med. 8 (2015) 9512–9518.
[15] G. Mozes, K.J. Carlee, C.M. Rowland, J.A. van Heerden, G.B. Thompson, C. S. Grant, et al., The predictive value of laboratory findings in patients with primary hyperparathyroidism, J. Am. Coll. Surg. 194 (2002) 126–130.
[16] I. Nawrot, W. Chudzinski, T. Ciaçka, M. Barczyński, J. Samidt, Reoperations for persistent or recurrent primary hyperparathyroidism: results of a retrospective cohort study at a tertiary referral center, Med Sci Monit Int Med J Exp Clin Res 20 (2014) 1604–1612.
[17] B. Sun, B. Guo, B. Wu, J. Kang, X. Deng, Z. Zhang, et al., Characteristics, management, and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Nail Osteoporos Found USA 29 (2018) 635–642.
[18] Y. Tomasina, L. Grimalius, H. Johansson, C. Rudberg, H. Johansson, S. Ljunghall, et al., Histological and clinical features of non-familial primary parathyroid hyperplasia, Pathol. Res. Pract. 188 (1992) 115–122.
[19] H. Chen, T.S. Wang, T.W.F. Yen, K. Doff, E. Kryweda, S. Schaefer, et al., Operative failures after parathyroidectomy for hyperparathyroidism: the influence of surgical volume, Ann. Surg. 252 (2010) 691–695.
[20] Y. Tomasina, T. Tsuruki, K. Uchida, T. Haba, S. Otoska, T. Ichimori, et al., Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma, Kidney Int. 55 (1999) 1375–1385.
[21] F. Rici, P.L. Mingazzini, V. Sebastiani, E. D’Erasmo, C. Letizia, G. De Toma, et al., p53 as a marker of differentiation between hyperplastic and adenomatous parathyroids, Ann. Diagn. Pathol. 6 (2002) 229–233.
[22] M.D. Jovanovic, V.R. Zivaljevic, A.D. Diklic, B.R. Rovcanin, G. V Zoric, I. Ravac, Surgical treatment of concomitant thyroid and parathyroid disorders: analysis of 4882 cases, Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. 274 (2017) 997–1004.
[23] S. Ryan, D. Courtney, C. Timon, Co-existent thyroid disease in patients treated for primary hyperparathyroidism: implications for clinical management, Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg 272 (2015) 419–423.